Publications en collaboration avec des chercheurs de University of Pennsylvania (42)

2024

  1. AI is a viable alternative to high throughput screening: a 318-target study

    Scientific Reports, Vol. 14, Núm. 1

  2. Correction to: AI is a viable alternative to high throughput screening: a 318-target study (Scientific Reports, (2024), 14, 1, (7526), 10.1038/s41598-024-54655-z)

    Scientific Reports

  3. International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma

    The Lancet Oncology, Vol. 25, Núm. 5, pp. e205-e216

2023

  1. Ceramide synthase 6 (CerS6) is upregulated in alcohol-associated liver disease and exhibits sex-based differences in the regulation of energy homeostasis and lipid droplet accumulation

    Molecular Metabolism, Vol. 78

  2. Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways

    Cancer Discovery, Vol. 13, Núm. 11, pp. 2370-2393

  3. Correction: “The 5th edition of The World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms” Leukemia. 2022 Jul;36(7):1720–1748 (Leukemia, (2022), 36, 7, (1720-1748), 10.1038/s41375-022-01620-2)

    Leukemia

  4. Translational considerations for immunotherapy clinical trials in pediatric neuro-oncology

    Neoplasia (United States), Vol. 42

  5. Viral vector–mediated expression of NaV1.1, after seizure onset, reduces epilepsy in mice with Dravet syndrome

    Journal of Clinical Investigation, Vol. 133, Núm. 12

2022

  1. Complement C5a induces the formation of neutrophil extracellular traps by myeloid-derived suppressor cells to promote metastasis

    Cancer Letters, Vol. 529, pp. 70-84

  2. Mutant IDH Inhibits IFNg–TET2 Signaling to Promote Immunoevasion and Tumor Maintenance in Cholangiocarcinoma

    Cancer Discovery, Vol. 12, Núm. 3, pp. 812-835

  3. Perspectives in Immunotherapy: meeting report from the Immunotherapy Bridge, December 1st–2nd, 2021

    Journal of Translational Medicine, Vol. 20, Núm. 1

  4. Targeting the EIF2AK1 Signaling Pathway Rescues Red Blood Cell Production in SF3B1-Mutant Myelodysplastic Syndromes With Ringed Sideroblasts

    BLOOD CANCER DISCOVERY, Vol. 3, Núm. 6

2021

  1. International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials

    Leukemia, Vol. 35, Núm. 1, pp. 18-30

  2. The 2020 BMT CTN Myeloma Intergroup Workshop on Immune Profiling and Minimal Residual Disease Testing in Multiple Myeloma

    Transplantation and Cellular Therapy, Vol. 27, Núm. 10, pp. 807-816

  3. The Nuclear Receptor ESRRA Protects from Kidney Disease by Coupling Metabolism and Differentiation

    Cell Metabolism, Vol. 33, Núm. 2, pp. 379-394.e8

2020

  1. H3K27ac acetylome signatures reveal the epigenomic reorganization in remodeled non-failing human hearts

    Clinical Epigenetics, Vol. 12, Núm. 1

  2. Liver-specific ceramide reduction alleviates steatosis and insulin resistance in alcohol-fed mice

    Journal of Lipid Research, Vol. 61, Núm. 7, pp. 983-994

  3. Repurposing the yellow fever vaccine for intratumoral immunotherapy

    EMBO Molecular Medicine, Vol. 12, Núm. 1

2019

  1. Author Correction: ‘Stealth’ corporate innovation: an emerging threat for therapeutic drug development (Nature Immunology, (2019), 20, 11, (1409-1413), 10.1038/s41590-019-0503-1)

    Nature Immunology

  2. Complementing the cancer-immunity cycle

    Frontiers in Immunology, Vol. 10, Núm. APR